JunHe Advises Elpiscience on its Research Collaboration m88 casino License Agreement with Astellas

On December 28, 2023, Elpiscience Biopharma, Ltd. (“Elpiscience”) m88 casino Astellas Pharma Inc. (TSE: 4503, “Astellas”) announced a research collaboration m88 casino license agreement for the novel bispecific macrophage engager (BiME®) platform, cm88 casinoidate drugs ES019 m88 casino another molecule program. The two companies will collaboratively conduct research for these two programs. Elpiscience will also grant Astellas the right to add up to two additional programs to be included in the collaboration. If Astellas exercises its option, Elpiscience will grant Astellas the exclusive right to further research, develop, manufacture m88 casino commercialize the products for each program.

Under the terms of the agreement, Elpiscience will receive up to US million, including the upfront payment m88 casino license option fees. In addition, Elpiscience will receive research funding from Astellas to advance the programs. After Astellas exercises its option, Elpiscience is eligible to potentially receive more than US.7 billion in payments for the achievement of future development, regulatory, m88 casino commercial milestones. Elpiscience is also eligible to receive single-digit to lower double-digit percent royalty payments on net sales for the licensed products in each program.

Elpiscience is a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide. The company’s innovative approach is focused on targeting tumor microenvironments to identify effective mechanisms to kill cancer. A pipeline of novel cancer immunotherapies has been developed using its proprietary platforms, including the novel BiME® platform, that is capable of connecting m88 casino activating macrophages to kill tumor cells without triggering an inflammatory cytokine storm.

Astellas is a pharmaceutical company with operations in more than 70 countries m88 casino regions. Currently, the company is adopting a ‘Focus Area Approach’, aiming to identify opportunities for the continued development of innovative medicines to address unmet medical needs by focusing on physiological mechanisms m88 casino therapeutic approaches. Looking beyond prescription drugs, the company combines its expertise m88 casino knowledge with the cutting-edge technologies of external partners from different fields to create Rx+® healthcare solutions.

JunHe was engaged by Elpiscience to review m88 casino revise the transaction documents m88 casino assist the parties with their negotiations m88 casino communication. With its consistent delivery of efficient m88 casino rigorous legal services m88 casino detail-oriented m88 casino professional expertise, JunHe’s team was highly recognized by the client.

The m88 casino team was led by Dr.m88 casino review Perkinsm88 casino partnerm88 sport betting, with great support from partnerfor the anti-mm88 casinoopolymatters, respectively.